Source: CVC IN KANSAS CITY PROCEEDINGS
August 1, 2010
By:
Michael D. Apley, DVM, PhD, DACVCP
These proceedings present data related to the question of how long to wait after administering a single injection antimicrobial before applying success/failure criteria. More accurately, we will evaluate success/failure and mortality data based on administering a uniform regimen and then waiting different periods before applying success/failure criteria, and the animal subsequently being eligible for further therapy.
|
Source: CVC IN KANSAS CITY PROCEEDINGS
August 1, 2010
By:
Virginia R. Fajt, DVM, PhD
Drugs approved in the U.S. specifically for analgesia in cattle do not exist. There are guidance documents from the FDA Center for Veterinary Medicine for companies that would like to have an NSAID approved for pain relief
|
Source: CVC IN KANSAS CITY PROCEEDINGS
August 1, 2010
By:
Mark L. Alley, DVM, MBA
Developing herd health programs for cow-calf operations can be time consuming but rewarding for both the producer and the veterinarian if done appropriately. However, many producers think of a herd health program as only a vaccine program. Interestingly, the vaccination schedule and the vaccines that will be used constitute the smallest portion of a true herd health program.
|
Source: CVC IN KANSAS CITY PROCEEDINGS
August 1, 2010
By:
Robert Larson, DVM, PhD, DACT, DACVPM
Suckling calves are commonly in contact with the breeding herd during early gestation, prior to the time the bovine fetus develops a competent immune system. As a result, PI suckling calves are considered to be the primary source of BVDV infection in breeding herds causing pregnancy loss, pre-weaning mortality and the induction of PI calves in the next generation.
|
Source: CVC IN KANSAS CITY PROCEEDINGS
August 1, 2010
By:
Virginia R. Fajt, DVM, PhD
In most cases, we administer drugs at a different site than we want to drug to act. Understanding how drugs get to their site of action and how long they stay there is essential to making therapeutic decisions about which drug, what route, how much, how often, and for how long.
|
Source: CVC IN KANSAS CITY PROCEEDINGS
August 1, 2010
By:
Michael D. Apley, DVM, PhD, DACVCP
This presentation attempts to summarize some of the major concerns in resistance development along with key articles explaining relevance, epidemiology, and prevalence. It is not intended to be an exhaustive review of the literature and the interested practitioner should use the cited literature herein as a basis for continued, extended reading.
|
Source: CVC IN KANSAS CITY PROCEEDINGS
August 1, 2010
By:
Virginia R. Fajt, DVM, PhD
The design of antimicrobial regimens is addressed in the next section in these proceedings, but the concepts within regimen design related to determining the concentration of drug required to inhibit growth of bacterial pathogens deserve a more thorough discussion.
|
Source: CVC IN KANSAS CITY PROCEEDINGS
August 1, 2010
By:
Michael D. Apley, DVM, PhD, DACVCP
The capacity to experience pain is considered to have a protective role by eliciting behavioral responses aimed at reducing further tissue damage and enhance wound healing. However, persistent pain syndromes offer no biological advantage and are associated with suffering and distress.
|
Source: CVC IN KANSAS CITY PROCEEDINGS
August 1, 2010
By:
Virginia R. Fajt, DVM, PhD
Bovine respiratory disease complex includes bacterial components, which cause the classic clinical signs of lethargy, depression, and fever, with variable nasal discharge, cough, or other signs. This bacterial component of BRD (most commonly Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis) may be treated with antimicrobial drugs designed to kill or inhibit the growth of the pathogenic bacteria.
|
|
